Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice

Circulation

Volumn 124, Issue 5, 2011, Pages 582-588

  Rafael Fortney, Jill A ^a,b   Chimanji, Neeraj S ^b   Schill, Kevin E ^b   Martin, Christopher D ^b   Murray, Jason D ^b   Ganguly, Ranjit ^b   Stangland, Jenna E ^b   Tran, Tam ^a,b   Xu, Ying ^b   Canan, Benjamin D ^b   Mays, Tessily A ^b   Delfín, Dawn A ^b   Janssen, Paul M L ^a,b   Raman, Subha V ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cardiomyopathy muscles aldosterone antagonists

Indexed keywords

ANTIFIBROTIC AGENT; DYSTROPHIN; GELATINASE; IMMUNOGLOBULIN G; LISINOPRIL; SPIRONOLACTONE; UTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CHRONOTHERAPY; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EARLY INTERVENTION; EX VIVO STUDY; EXTENSOR DIGITORUM LONGUS MUSCLE; HAPLOINSUFFICIENCY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PROTECTION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUSCLE FUNCTION; MUSCLE INJURY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKELETAL MUSCLE; THERAPY DELAY;

ANIMALS; CARDIAC IMAGING TECHNIQUES; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DIURETICS; ISOPROTERENOL; LISINOPRIL; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; SPIRONOLACTONE;

EID: 80051552743     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.031716     Document Type: Article

References (24)

1. Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Circ Cardiovasc Imaging. 2011;4:67-76.
2. English KM, Gibbs JL. Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders. Dev Med Child Neurol. 2006; 48:231-235. (Pubitemid 44404273)
3. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. June 7-9, 2002, Naarden, the Netherlands. Neuromuscul Disord. 2003;13:166-172.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC, Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235.
5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2010;364:11-21.
6. Hor KN, Wansapura J, Markham LW, Mazur W, Cripe LH, Fleck R, Benson DW, Gottliebson WM. Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol. 2009;53: 1204-1210.
7. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-1393.
8. Sanderson JE. New treatments for myocardial fibrosis. Cardiovasc Drugs Ther. 2002;16:181-182. (Pubitemid 35398617)
9. Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB, Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007;50:591-596. (Pubitemid 47199012)
10. Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X, Kaminski HJ, Liu L, Ransohoff RM. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci. 2008;264:106-111. (Pubitemid 350186318)
11. Hainsey TA, Senapati S, Kuhn DE, Rafael JA. Cardiomyopathic features associated with muscular dystrophy are independent of dystrophin absence in cardiovasculature. Neuromuscul Disord. 2003;13: 294-302. (Pubitemid 36966160)
12. Janssen PML, Hiranandani N, Mays TA, Rafael-Fortney JA. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophindeficient mdx mice. Am J Physiol Heart Circ Physiol. 2005;289: H2373-H2378. (Pubitemid 41698545)
13. Hor KN, Gottliebson WM, Carson C, Wash E, Cnota J, Fleck R, Wansapura J, Klimeczek P, Al-Khalidi HR, Chung ES, Benson DW, Mazur W. Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis. J Am Coll Cardiol Cardiovasc Imaging. 2010;3:144-151.
14. Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar BK, Delfín DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, Flood P, Kaumaya P, Frietas M, Kornegay JN, Mendell JR, Rafael-Fortney JA, Guttridge DC, Janssen PML. Peptide-based inhibition of NF-B rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med. 2011;17:508-515.
15. Rodino-Klapac LR, Janssen PM, Montgomery CL, Coley BD, Chicoine LG, Clark KR, Mendell JR. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med. 2007;5:45.
16. Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, Su JT, Pack N, Dibella E, Gottliebson WM. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy? Int J Cardiovasc Imaging. 2009;25:57-63.
17. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991;352:536-539.
18. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77-93.
19. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008; CD003725.
20. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18:365-370.
21. Marques MJ, Oggiam DS, Barbin IC, Ferretti R, Santo Neto H. Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve. 2009;40:466-468.
22. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA. Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail. 2009;11:463-471.
23. Guerron AD, Rawat R, Sali A, Spurney CF, Pistilli E, Cha HJ, Pandey GS, Gernapudi R, Francia D, Farajian V, Escolar DM, Bossi L, Becker M, Zerr P, de la Porte S, Gordish-Dressman H, Partridge T, Hoffman EP, Nagaraju K. Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne muscular dystrophy. PLoS One. 2010;5:e11220.
24. Hartel JV, Granchelli JA, Hudecki MS, Pollina CM, Gosselin LE. Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. Muscle Nerve. 2001;24:428-432.